KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 90 filers reported holding KALVISTA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $41,000 | +2.5% | 4,226 | -5.9% | 0.00% | – |
| Q2 2023 | $40,000 | +263.6% | 4,492 | +225.7% | 0.00% | – |
| Q1 2023 | $11,000 | -62.1% | 1,379 | -68.2% | 0.00% | – |
| Q4 2022 | $29,000 | -79.7% | 4,332 | -56.0% | 0.00% | – |
| Q3 2022 | $143,000 | +14200.0% | 9,847 | +7035.5% | 0.00% | – |
| Q2 2022 | $1,000 | -95.0% | 138 | -90.0% | 0.00% | – |
| Q1 2022 | $20,000 | -69.7% | 1,376 | -72.3% | 0.00% | – |
| Q4 2021 | $66,000 | +61.0% | 4,971 | +113.8% | 0.00% | – |
| Q3 2021 | $41,000 | -41.4% | 2,325 | -19.8% | 0.00% | – |
| Q2 2021 | $70,000 | +52.2% | 2,900 | +62.2% | 0.00% | – |
| Q1 2021 | $46,000 | +253.8% | 1,788 | +166.9% | 0.00% | – |
| Q4 2020 | $13,000 | – | 670 | +3090.5% | 0.00% | – |
| Q3 2020 | $0 | – | 21 | -34.4% | 0.00% | – |
| Q1 2020 | $0 | -100.0% | 32 | -97.5% | 0.00% | – |
| Q4 2019 | $22,000 | – | 1,263 | +12530.0% | 0.00% | – |
| Q3 2018 | $0 | – | 10 | +900.0% | 0.00% | – |
| Q1 2017 | $0 | – | 1 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SV Health Investors, LLC | 1,719,576 | $25,679,000 | 12.37% |
| Vivo Capital, LLC | 1,618,296 | $30,731,000 | 1.37% |
| Opaleye Management Inc. | 470,203 | $8,929,000 | 1.17% |
| INTERWEST VENTURE MANAGEMENT CO | 388,766 | $7,383,000 | 0.92% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 177,433 | $3,369,000 | 0.92% |
| Ikarian Capital, LLC | 1,063,961 | $20,204,000 | 0.89% |
| Ghost Tree Capital, LLC | 200,000 | $3,798,000 | 0.85% |
| Logos Global Management LP | 490,000 | $9,305,000 | 0.80% |
| Eventide Asset Management | 1,680,000 | $31,903,000 | 0.49% |
| Affinity Asset Advisors, LLC | 45,000 | $855,000 | 0.45% |